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The efficiency of first-generation adenoviral vectors as gene delivery
tools is often limited by the short duration of transgene expression,
which can be related to immune responses and to toxic effects of viral
proteins. In addition, readministration is usually ineffective unless the
animals are immunocompromised or a different adenovirus serotype
is used. Recently, adenoviral vectors devoid of all viral coding se-
quences (helper-dependent or gutless vectors) have been developed
to avoid expression of viral proteins. In mice, liver-directed gene
transfer with AdSTK109, a helper-dependent adenoviral (Ad) vector
containing the human a1-antitrypsin (hAAT) gene, resulted in sus-
tained expression for longer than 10 months with negligible toxicity
to the liver. In the present report, we have examined the duration of
expression of AdSTK109 in the liver of baboons and compared it to
first-generation vectors expressing hAAT. Transgene expression was
limited to approximately 3–5 months with the first-generation vec-
tors. In contrast, administration of AdSTK109 resulted in transgene
expression for longer than a year in two of three baboons. We have
also investigated the feasibility of circumventing the humoral re-
sponse to the virus by sequential administration of vectors of differ-
ent serotypes. We found that the ineffectiveness of readministration
due to the humoral response to an Ad5 first-generation vector was
overcome by use of an Ad2-based vector expressing hAAT. These data
suggest that long-term expression of transgenes should be possible
by combining the reduced immunogenicity and toxicity of helper-
dependent vectors with sequential delivery of vectors of different
serotypes.
Numerous studies with adenoviral vectors in a variety of animalmodels have demonstrated successful gene transfer to many
tissues, with high levels of expression of recombinant genes, making
these vectors attractive candidates for treating a variety of human
diseases (1–5). However, use of first-generation vectors usually
results in only transient transgene expression. This is partially due
to the development of a cellular immune response triggered by viral
proteins expressed from adenovirus genes (1, 4, 6, 7). Other factors
that can limit persistence of transgene expression are immune
responses to the transgene product (8–10), the dose of virus
administered (10, 11), the promoter chosen to drive expression of
the recombinant gene (12–14), innate immune mechanisms (15–
17), and direct cytotoxicity caused by expression of viral genes
(18–20).
One strategy to reduce the immunogenicity of the vector has
been to delete all viral coding sequences so that leaky expression of
viral proteins is completely eliminated (21–24). Recently, helper-
dependent systems have been developed that use a first-generation
helper virus to provide the necesary proteins in trans for the
packaging of a vector devoid of viral genes (25, 26). One of these
helper-dependent vectors has been used in mice to deliver the
human a1-antitrypsin gene to the liver, and expression was sus-
tained for longer than 10 months (19). In addition, administration
of high doses resulted in negligible toxicity to the liver (18, 27).
Therefore, by using helper-dependent vectors, it may be possible
to develop a gene therapy strategy that would require readminis-
tration only after long periods of time. Unfortunately, the devel-
opment of neutralizing antibodies against the adenovirus capsid
proteins after the first injection precludes transgene expression with
readministration unless the animal is immunocompromised (28–
31). One approach to circumvent this problem involves the use of
vectors of different serotypes (32, 33).
In the present report, we have examined the duration of expres-
sion after intravenous injection aimed at hepatic gene transfer in
baboons, using first generation and helper-dependent adenoviral
vectors expressing human a1-antitrypsin (hAAT). We have also
addressed the feasibility of administering a vector of a different
serotype. Our results indicate that alternative delivery of helper-
dependent adenoviral vectors from different serotypes is a prom-
ising strategy for very long-term gene therapy treatment of human
diseases.
Materials and Methods
Vectors. The construction of adenovirus (Ad) vectors
Ad5hAATDE1 and AdSTK109 has been described (19, 34).
Ad5hAATDE1 is a serotype 5, E1-deleted vector with an expres-
sion cassette consisting of the hAAT cDNA under control of the
murine phosphoglycerate kinase promoter (34). Ad2hAATDE1 is
a serotype 2 (35), first-generation vector containing an expression
cassette identical to that of Ad5hAATDE1. AdSTK109 is a helper-
dependent adenoviral vector containing the complete hAAT gene
locus, including the endogenous promoter, all exons and introns,
and the natural polyadenylation signal (19). Ad5hAATDE1 and
Ad2hAATDE1 were produced in 293 cells, and AdSTK109 in
293Cre cells (25, 36). All vector preparations were evaluated by
particle count as determined by optical density measurement of
DNA. The level of helper contamination in AdSTK109 prepara-
tions was determined by plaque assay and found to be ,0.1%. The
presence of replication-competent adenovirus in AdSTK109 prep-
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arations was determined as described (19) and was ,1 particle in
2 3 108 particles.
Experimental Animals and Specimen Collection. The baboons used in
this study were Papio sp., males, 4 months to 2 years old at the time
of the first virus administration. A total of nine animals was used
in the study, each with a unique recognition number (Table 1).
Before vector administration, the animals were sedated with 10
mgykg ketamine. A 22 gauge catheter was placed in the right
saphenous vein, and the appropriate amount of vector (doses
specified in Table 1) was infused, followed by flushing with 5 ml of
sterile saline. Five milliliters of blood was obtained from the
cephalic vein on days 0, 3, 10, and then weekly after vector
administration, to perform blood cell counts and blood chemistries
(glucose, blood urea nitrogen, creatinine, total protein, albumin,
globulin, AyG ratio, cholesterol, alanine aminotransferase, aspar-
tate aminotransferase, alkaline phosphatase, Na1, K1, Cl2, CO2,
anion gap, total bilirubin), to measure hAAT levels, and to test
serum for the presence of neutralizing antibodies to the virus
capsid. Baboons receiving AdSTK109 were bled only once a month
from the third month after vector administration. The animals were
monitored for general health, including appetite, stool consistency,
tachycardia, loss of weight, presence of fever, conjunctivitis, or any
abnormal sign that could be related to administration of the vectors.
The animals were individually caged in animal biosafety level 2
(ABSL2) containment until no vector was recovered from feces for
4 consecutive weeks (approximately 2 months after administra-
tion), and were then transferred to an ABSL1 containment.
Feces were collected at the times of blood withdrawal to be
analyzed for the presence of Ad5hAATDE1 and Ad2hAATDE1
vectors as described (37).
ELISA for hAAT. An ELISA was used to measure the levels of hAAT
in serum as described for mouse studies (10, 38). Because the
antibody against hAAT used was found to cross-react weakly with
baboon AAT, a modification was introduced to the assay. The
peroxidase-conjugated antibody was treated with naive baboon
serum to eliminate the fraction of antibody that cross-reacts with
baboon AAT. A 1:300 dilution of naive baboon serum was used for
most assays; the dilution was changed to 1:2,400 when a different
batch of anti-hAAT antibody was purchased. Naive serum and the
secondary antibody were mixed and left at room temperature for
1.5 hours before use.
Anti-hAAT Antibody Detection. An ELISA assay was used to detect
antibodies to hAAT in serum as described (10).
Neutralizing Antibody Titers. Dilutions of serum samples were
tested for the presence of neutralizing antibodies that prevented
transduction of wild-type Ad5 and Ad2 on HEp2 cells (37).
Serial 1:2 dilutions (starting from a 1:8 dilution) were mixed with
wild-type adenovirus and incubated at 37°C for 1 hour. HEp2
cells (2–4 3 104) were then added to the wells and incubated at
37°C. The titer was determined as the highest dilution at which
$90% reduction in cytopathic effect occurred compared with a
negative control (no serum added). Serum samples with unde-
tectable neutralizing antibodies at the 1:8 dilution were assigned
a titer of 1:4.
Cytotoxic T Lymphocyte Assay. Spleen cells were stimulated with 5 3
107 units of Ad2hAATDE1 for 7 days to promote antigen-specific
expansion of cytotoxic T lymphocyte (CTLs). Recombinant human
IL-2 was added at 20 unitsyml on day 4 of culture. Target fibroblasts
derived from skin biopsies of baboons 12490 and 12497 were
infected at a multiplicity of infection of 100 for 48 hours and were
treated with 500 unitsyml recombinant human IFN-g for the last 24
hours to enhance MHC class I expression and antigen presentation
to effector CTLs. Fibroblasts were labeled with 51Cr by overnight
incubation at 37°C. Splenocytes and target cells were incubated at
ratios of 80:1, 40:1, 20:1, and 10:1 for 5 hours. Infected allogeneic
fibroblasts were also used as targets to confirm MHC class I-re-
stricted cytolytic activity. The amount of 51Cr spontaneously re-
leased was obtained by incubating target fibroblasts in medium
alone; the total amount of 51Cr incorporated was determined by
adding 1% Triton X-100. The percentage of lysis was calculated as
follows: lysis % 5 [(sample cpm) 2 (spontaneous cpm)]y[(total
cpm) 2 (spontaneous cpm)] 3 100.
Proliferation Assay. Spleen cells from each animal were plated in
triplicate in a 96-well plate (5 3 105 cells per well). The cells were
incubated with medium alone (background) or stimulated with 5
mgyml heat-inactivated Ad2 vector in a total volume of 200 ml.
Cultures were incubated for 5 days at 37°C in 5% CO2 and pulsed
with 1 mCi per well (1 Ci 5 37 GBq) [3H]thymidine for the last 18
hours of incubation. Cells were harvested onto glass fiber filters
with a 96-well plate cell harvester, and cell-associated radioactivity
was measured by liquid scintillation counting.
Results
Short-Term Expression After Administration of a First-Generation Vector.
Preliminary data in baboons indicated that intravenous admin-
istration of a first-generation vector expressing Escherichia coli
b-galactosidase results in transduction primarily in the liver (data
not shown). To determine persistence of transgene expression,
Table 1. Experimental design
Subject
Ad5hAATDE1





























12402 6.2 3 1011 6 2.06 2.8 3 1011 12 4.13 6.2 3 1011 24 6.10 — — —
12486 6.2 3 1011 4 1.81 2.8 3 1011 10 3.78 7.2 3 1011 22 6.00 — — —
12490 1.4 3 10
12
8 2.76 — — — 6 3 1011 27.5 6.53 — — —
12497 1.4 3 1012 8 2.65 — — — 6 3 1011 27.5 6.80 — — —
13110 — — — — — — 6.1 3 1011 20.5 5.77 — — —
13121 — — — — — — 6.1 3 1011 20.5 5.65 — — —
13250 — — — — — — — — — 3.3 3 1011 10 3.87
13277 — — — — — — — — — 3.9 3 1011 9 3.30
13729 — — — — — — — — — 3.6 3 1011 7.5 2.84
For each injection, the dose in particles per kg is given followed by the age in months and the weight of the animal in kg.































two baboons (12402 and 12486) were injected intravenously with
a dose of 6.2 3 1011 particles per kg of body weight ('2 3 1010
plaque-forming unitsykg) of Ad5hAATDE1, a first-generation
vector expressing hAAT (34) (Table 1). Expression was highest
at 3 days and declined slowly for a period of 3 months (Fig. 1).
In a second set of experiments, two baboons (12490 and 12497)
were injected with 2-fold higher amounts of Ad5hAATDE1
(Table 1). Expression of hAAT was higher and lasted longer than
in the baboons receiving the lower dose (Fig. 1). The differences
in the level and persistence of expression between the two groups
are unlikely to be significant, because only two animals per group
were treated.
The four animals were monitored at all times for their general
health and for the presence of any abnormal behavior that could be
related to the administration of the virus. No abnormal symptoms
were observed in any of the four animals; all thrived and gained
weight normally. Blood chemistries were analyzed at the same time
points at which hAAT was measured. No consistent or significant
changes in any of the parameters analyzed were observed in any of
the four animals, and in no case were they substantially different
from normal ranges. Platelets decreased in the four animals 3 days
after vector administration [values for preinjection3 3 days (3 103
per ml): 4363 294, 5633 280, 5693 152, 2933 189] but stayed
within normal range (130–400 3 103 per ml). A transient drop in
platelet counts has also been reported in mice at doses equal to or
higher than 3 3 1012 particles per kg Ad5hAATDE1 (39). The
decrease in platelet counts was believed to be a consequence of
endothelial cell damage and correlated with viral dose (39).
Feces were collected for 45 days to determine the period of time
of vector shedding. The Ad5hAATDE1 vector was recovered from
the feces of two of the baboons (12402 and 12490) at 3, 10, and 17
days, but after this period virus was not recovered at any time point
(data not shown).
Development of Neutralizing Antibodies Prevents a Second Adminis-
tration. Neutralizing antibodies against the vector developed in the
four animals (Table 2). The titers were between 1:32 and 1:128
(background level of the assay was 1:4). To determine if in vitro
neutralization titers correlated with in vivo protection to subsequent
infections, we administered a second dose of Ad5hAATDE1 vector
Fig. 1. Expression of hAAT in baboons after administration of Ad5hAATDE1 and Ad2hAATDE1. Baboons 12402, 12486, 12490, and 12497 received Ad5hAATDE1
followed by Ad2hAATDE1 at the doses indicated in Table 1. Two naive animals of similar age and weight (13110 and 13121) were used as controls for Ad2hAATDE1
administration. Arrows indicate the time of vector injection.
Table 2. Neutralizing antibody titer to Ad2 and Ad5
Subject
Ad5hAATDE1 administration Ad2hAATDE1 administration
day 0 day 24 day 87 day 0 day 17 day 52
Titer to wild-type Ad5
12402 ND 1:90 1:90 1:90 1:362 1:362
12486 1:4 1:128 1:32 1:64 1:362 1:181
12490 1:4 ND 1:64 1:64 1:256 1:90
12497 1:4 ND 1:90 1:128 1:512 1:181
Titer to wild-type Ad2
12402 1:4 1:16 1:23
12486 1:4 1:90 1:90
12490 1:4 1:64 1:32
12497 1:4 1:64 1:90
ND, not determined.





















(2.8 3 1011 particles per kg) to baboons 12402 and 12486. No
increase in hAAT levels was observed in the two animals (Fig. 1),
indicating that the antibodies induced by the first injection pre-
cluded expression from a second administration.
A Serotype 2 Vector Circumvents Neutralizing Antibodies to Sero-
type 5. To test whether the neutralizing antibodies developed
against Ad5hAATDE1 could be circumvented by using a vector of
a different serotype, the four baboons were injected with
Ad2hAATDE1, a serotype 2 vector expressing hAAT. All four
previously treated baboons (i.e., 12402, 12486, 12490, and 12497)
received a dose of Ad2hAATDE1 between 6 3 1011 and 7.2 3 1011
particles per kg (Table 1). As controls, two naive baboons received
a dose of 6.1 3 1011 particles per kg Ad2hAATDE1 (Table 1). All
four animals previously treated with Ad5hAATDE1 demonstrated
substantial expression of hAAT in response to the Ad2 vector (Fig.
1). Levels of expression declined at approximately the same rate
observed after administration of Ad5hAATDE1 and in a similar
way to the naive animals (Fig. 1). All of the animals developed
neutralizing antibodies to serotype 2 (Table 2), and interestingly,
the titer to serotype 5 also increased after administration of
Ad2hAATDE1, even though no neutralizing antibodies to Ad2
were detected before Ad2 administration (Table 2). Heterotypic
antibody responses have been observed in human adults for ad-
enoviruses within the same subgroup (40). Because Ad2 and Ad5
belong to subgroup C, it is very likely that the observed increase in
the titer to Ad5 is the result of antigenic relationships between the
two serotypes.
One of the naive baboons injected with Ad2hAATDE1 (number
13121) had high levels of alanine aminotransferase, aspartate
aminotransferase, alkaline phosphatase, g glutamyl transpeptidase,
and cholesterol (preinjection and abnormal values on week 6 after
injection were 523 415 unitsyliter, 313 129 unitsyliter, 1,6323
5,070 unitsyliter, 69 3 779 unitsyliter, and 96 3 203 mgydl,
respectively) for a period of 60 days, starting 4 weeks after vector
administration. However, the animal did not show external signs of
disease or discomfort, had normal appetite, and gained weight as
expected. The fact that the second baboon injected with the same
dose and batch of vector (baboon 13110) did not develop any
abnormal symptoms suggests that the altered values were most
probably not related to Ad2hAATDE1 administration.
Cellular Immune Responses to Adenoviral Vectors in Baboons. To
determine whether a cellular immune response to adenovirus
antigens had developed after administration of first-generation
vectors Ad5hAATDE1 and Ad2hAATDE1, animals 12490 and
12497 were sacrificed 4.5 months after injection of Ad2hAATDE1
to perform adenovirus-specific proliferation assays and CTL assays.
Spleen cells from both baboons responded significantly to Ad2
antigens, as determined in the proliferation assay (Fig. 2A), which
mainly indicates the presence of Ad2-specific CD41 T cells. How-
ever, CTLs against cells transduced with vector were only detected
in baboon 12497, and the percentage of lysis was relatively low (15%
lysis compared with 5.3% lysis in background wells at an EyT ratio
of 80:1; Fig. 2B). The inability to detect CTLs in baboon 12490 and
the low response in baboon 12497 could be due to the fact that the
animals were sacrificed long after the administration of
Ad2hAATDE1 ('4.5 months), when expression was no longer
detectable and CTL stimulation, therefore, was likely to be mini-
mal. Another explanation could be the fact that a relatively low dose
of vector was injected in the animals.
Long-Term Expression with a Helper-Dependent Adenoviral Vector.
To evaluate whether the helper-dependent vector AdSTK109
would persist in a large animal model, we administered '4 3 1011
particles per kg of AdSTK109 to three baboons. In two of the
animals (13277 and 13729), maximum levels of hAAT were ob-
served after 3–4 weeks ('3–4 mgyml), and these levels decreased
very slowly over time (Fig. 3). Both animals expressed hAAT for a
period longer than a year and will continue to be studied until
expression drops to baseline levels. The concentration of hAAT in
these baboons declined approximately to 8% (baboon 13277) and
19% (baboon 13729) of highest levels after 24 and 16 months,
respectively.
The third baboon injected with AdSTK109 (baboon 13250) had
much lower levels of hAAT in the serum, and expression in this
animal dropped to undetectable levels after '2 months. We
hypothesized that the rapid decline in transgene expression in this
animal could have been due to the development of antibodies to
hAAT, because we previously observed this phenomenon in mice
(10). The serum of the three baboons that received AdSTK109 and
the serum of baboons that received Ad5hAATDE1 were analyzed
for the presence of antibodies to hAAT. Only samples from baboon
13250 had detectable antibodies, and the titer increased from 1:50
at week 8 to 1:5,000 at week 12, suggesting that the antibodies to
hAAT were indeed the likely cause of the decrease in hAAT in this
baboon.
Blood cell counts and blood chemistries were within normal
values at all times in the three animals. No alterations in platelet
counts was observed 3 days after vector administration, as had been
observed in animals that were injected with Ad5hAATDE1.
Discussion
For correction of genetic disorders and many other applications,
optimal gene-therapy vectors should be capable of efficiently trans-
ducing cells and persisting in the target tissue for a long time.
Although first-generation adenoviral vectors have proven to be
Fig. 2. Cellular immuneresponses toadenoviralantigens inbaboons12490and
12497.Baboonsweretreatedas indicated inFig.1andTable1.Bothanimalswere
sacrificed4.5monthsafterAd2hAATDE1 infusion.Splenocyteswererestimulated
in vitro as described in Materials and Methods section to perform proliferation
(A) and CTL (B) assays. Target cells were fibroblasts from skin biopsies of each
animal infected with Ad2hAATDE1 or uninfected. EyT ratio, effector:target ratio.































particularly efficient for targeting liver cells after intravenous
infusion (41–45), their usefulness has been limited by the elimina-
tion of transduced cells. Deletion of all viral genes from the vector
backbone has been a strategy to avoid the production of viral
proteins, and therefore, to prolong expression.
Initial in vivo studies with a vector that lacked E1, E2, E3, and late
gene expression suggested that the DNA was not stable in the
vector-transduced cells, leading to shorter transgene persistence
than with first-generation vectors (46). Even though the reasons for
the instability of such a construct have not been clearly determined,
other studies have demonstrated long-term transgene expression
from helper-dependent adenoviral vectors in the liver and in the
muscle of immunocompetent hosts (19, 27, 47–49). We show here
that helper-dependent vectors result in long-term expression after
gene transfer to the liver of a primate model. Two of three animals
(13277 and 13729) expressed hAAT for longer than a year. It is
relevant that one of them, baboon 13277, expressed hAAT for more
than 2 years, although at the present time, the level is ,10% of
initial values. The decrease in hAAT levels in these two baboons
can be partially explained by the fact that the animals were young
at the time of injection and growing, and therefore, a decrease in
the concentration of hAAT is correlative to the growth of the
animals. Another possibility is that cells transduced by the vector
are eliminated by immune-related factors. A recent report has
shown that psoralen-treated UV-crosslinked first-generation vec-
tors can stimulate the production of CTLs, suggesting that cells
infected with inactive vector can present antigens for recognition by
MHC class I molecules in the absence of viral replication or de novo
protein synthesis (50). Although unlikely, we cannot discount the
possibility that the slow decline in transgene expression in baboons
13277 and 13729 might have been due to CTL responses against
vector-transduced cells triggered by the proteins present in the
capsid of the virus.
The mechanisms whereby hAAT expression can persist for over
a year after a single intravenous dose of helper-dependent adeno-
viral vector are not entirely clear. The most likely possibility is that
the vector genome can persist in the nucleus for prolonged intervals,
so long as it is not diluted by cell division. Integration into the host
genome is unlikely for the majority of cells, given the very stable
persistence of expression compared with levels seen shortly after
injection. It is possible that chromosomal integration occurs at a low
level, and further studies are needed to assess this possibility.
We have previously shown in mice that the level of transgene
expression does not linearly correlate with the dose of AdSTK109
(18). We observed a striking threshold effect with peak levels of
hAAT of 50 mgyml at the lowest dose tested (6.3 3 1011 particles
per kg) compared with 6,407 mgyml at the highest dose injected
(168 3 1011 particles per kg) (18). This value represents a 128-fold
increase in expression in response to a 27-fold increase in dose.
Based on these data, the amount of hAAT that would be expected
in mice at the dose injected in the baboons (3.75 3 1011 particles per
kg) would be '10 mgyml, which is only slightly higher than what we
observed in baboons (3–4 mgyml). Thus, the level of expression in
baboons is relatively consistent with what would be expected for a
similar dose per kg body weight in mice. Since helper-dependent
vectors have been substantially less toxic than first-generation
vectors in all instances studied in mice to date (18, 19, 27), studies
to evaluate the toxicity and expression with higher doses of helper-
dependent vector administered to primates are of great importance.
Expression by first-generation vectors in baboons lasted only 3–5
months. The lack of detection of antibodies against hAAT in these
animals suggests that cellular immune responses directed against
viral proteins may have been generated, with the potential to
subsequently eliminate vector-transduced cells. This idea is sup-
ported by the presence of reactive CD41 T cells after in vitro
stimulation with viral antigens of spleen cells from baboons 12490
and 12497, which received Ad5hAATDE1 followed by
Ad2hAATDE1. It is interesting that we did not observe a faster
decrease in hAAT expression after Ad2hAATDE1 delivery in
animals previously challenged with Ad5hAATDE1. Human CTLs
raised against serotype 5 have been found to cross-react with other
serotypes in vitro, suggesting that in vivo, the memory cytotoxic
response raised against one serotype might not be evaded by
switching to a different serotype (51). We would have expected
shorter transgene expression if memory T cells activated after
delivery of Ad5hAATDE1 played an important role in eliminating
Ad2hAATDE1-transduced liver cells. However, it is possible that
the cytotoxic T cell response depends on the viral dose adminis-
tered and that at the dose of vector used in our experiments, the
response is not robust enough to observe a rapid decline in
transgene expression after Ad2hAATDE1 delivery. It is worth
noting that the potential amount of replication-competent adeno-
virus contamination in the vector preparations is negligible (103
particles) and that in mice it is not sufficient to induce a detectable
CTL response (J.K., unpublished results).
Fig. 3. Expression of hAAT in baboons after administration of Ad5hAATDE1 or AdSTK109. Treatment of the four animals that received Ad5hAATDE1 (12402, 12486,
12490, and 12497) is described in Fig. 1. Baboons 13250, 13277, and 13729 received 3.3 3 1011, 3.9 3 1011, and 3.6 3 1011 particles per kg, respectively, of AdSTK109
vector.





















If helper-dependent vectors of different serotypes were used for
gene transfer, cellular immune responses after multiple adminis-
trations would not be anticipated, because these vectors are devoid
of viral coding sequences. Recently, we have shown that expression
of hAAT is not affected by CTLs generated from three previous
administrations of serotype 5-based first generation vectors in mice
(W.O., unpublished results). In addition, mice lacking Ig production
treated with four consecutive doses of AdSTK109 did not have
decreased hAAT expression, indicating that cytotoxic immune
responses to helper-dependent vectors are unlikely to be developed
(W.O., unpublished results).
The pattern of hAAT expression observed in the animals that
received AdSTK109 suggests that readministration of vector will
probably be necessary to achieve lifetime expression of a therapeu-
tic gene with helper-dependent adenoviral vectors, although it may
be possible to achieve adequate therapy in some cases for 1–2 years
after a single injection. Delivery of a serotype 5 followed by
administration of a serotype 2 vector has been used for repeated
administration to the lung (52). In the present study, we have shown
that intravenous readministration of first-generation vectors in
baboons is possible using the two most common adenovirus sero-
types used in gene therapy studies, serotypes 2 and 5. Recently, an
Ad2-based helper-dependent vector has been developed (53). It
should be noted that Ad5 and Ad2 helper-dependent vectors can be
produced from the same starting vector plasmid by changing only
the helper virus. Therefore, multiple serotypes of helper-dependent
vectors may provide the opportunity for multiple years of corrective
therapy in many gene-therapy settings. This possibility, combined
with the previously reported improved safety, makes helper-
dependent vectors promising tools for the treatment of diseases that
require persistent expression of therapeutic genes.
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